Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial

The Lancet

Volumn 376, Issue 9749, 2010, Pages 1320-1328

  Wallentin, Lars ^a   James, Stefan ^a   Storey, Robert F ^b   Armstrong, Martin ^c   Barratt, Bryan J ^c   Horrow, Jay ^c   Husted, Steen ^d   Katus, Hugo ^e   Steg, P Gabriel ^f,g,h   Shah, Svati H ⁱ   Becker, Richard C ⁱ  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f INSERM   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h BICHAT HOSPITAL   (France)

ⁱ DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; DNA; MULTIDRUG RESISTANCE PROTEIN 1; TICAGRELOR; ABCB1 PROTEIN, HUMAN; ADENOSINE; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ACUTE CORONARY SYNDROME; AGED; ALLELE; ARTICLE; BLEEDING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; GENOTYPE; HEART DEATH; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; GENETICS; PHARMACOGENETICS; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACUTE CORONARY SYNDROME; ADENOSINE; AGED; ARYL HYDROCARBON HYDROXYLASES; CARDIOVASCULAR DISEASES; CYTOCHROME P-450 CYP2C19; FEMALE; GENOTYPE; HUMANS; MALE; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PHARMACOGENETICS; PHENOTYPE; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TICLOPIDINE;

EID: 77958100874     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)61274-3     Document Type: Article

References (33)

1. JL Anderson, CD Adams, EM Antman ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine Circulation 116 2007 e148 e304
2. JP Bassand, CW Hamm, D Ardissino Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes Eur Heart J 28 2007 1598 1660
3. FG Kushner, M Hand, SC Smith Jr 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 120 2009 2271 2306
4. F Van de Werf, J Bax, A Betriu Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology Eur Heart J 29 2008 2909 2945
5. SD Wiviott, E Braunwald, CH McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
6. JS Hulot, A Bura, E Villard Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247
7. P Savi, JM Pereillo, MF Uzabiaga Identification and biological activity of the active metabolite of clopidogrel Thromb Haemost 84 2000 891 896
8. P Savi, JM Herbert Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis Semin Thromb Hemost 31 2005 174 183
9. JL Mega, SL Close, SD Wiviott Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
10. AR Shuldiner, JR O'Connell, KP Bliden Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
11. C Varenhorst, S James, D Erlinge Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease Eur Heart J 30 2009 1744 1752
12. 12 inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin Am Heart J 157 2009 562.e1 562.e9
13. J-P Collet, J-S Hulot, A Pena Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
14. JS Hulot, JP Collet, J Silvain Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis J Am Coll Cardiol 56 2010 134 143
15. D Sibbing, W Koch, D Gebhard Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement Circulation 121 2010 512 518
16. D Taubert, N von Beckerath, G Grimberg Impact of P-glycoprotein on clopidogrel absorption Clin Pharmacol Ther 80 2006 486 501
17. T Simon, C Verstuyft, M Mary-Krause Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
18. S Husted, H Emanuelsson, S Heptinstall, PM Sandset, M Wickens, G Peters Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin Eur Heart J 27 2006 1038 1047
19. PA Gurbel, KP Bliden, K Butler Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 120 2009 2577 2585
20. RF Storey, S Melissa Thornton, R Lawrance Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3 Platelets 20 2009 341 348
21. L Wallentin, RC Becker, A Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
22. 12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial Am Heart J 157 2009 599 605
23. F Sofi, B Giusti, R Marcucci, AM Gori, R Abbate, GF Gensini Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis Pharmacogenomics J 2010 10.1038/tpj.2010.21 published online March 30.
24. HG Xie, RB Kim, AJ Wood, CM Stein Molecular basis of ethnic differences in drug disposition and response Annu Rev Pharmacol Toxicol 41 2001 815 850
25. G Ragia, KI Arvanitidis, A Tavridou, VG Manolopoulos Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece Pharmacogenomics 10 2009 43 49
26. MM Ameyaw, F Regateiro, T Li MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity Pharmacogenetics 11 2001 217 221
27. JL Mega, SL Close, SD Wiviott Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 2009 2553 2560
28. B Giusti, AM Gori, R Marcucci Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis Am J Cardiol 103 2009 806 811
29. D Sibbing, J Stegherr, W Latz Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention Eur Heart J 30 2009 916 922
30. D Trenk, W Hochholzer, MF Fromm Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 2008 1925 1934
31. A Owen, C Goldring, P Morgan, D Chadwick, BK Park, M Pirmohamed Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver Br J Clin Pharmacol 59 2005 365 370
32. S Hoffmeyer, O Burk, O von Richter Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci USA 97 2000 3473 3478
33. F Marin, R Gonzalez-Conejero, P Capranzano, TA Bass, V Roldan, DJ Angiolillo Pharmacogenetics in cardiovascular antithrombotic therapy J Am Coll Cardiol 54 2009 1041 1057